Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Toxicity, Drug

Tundra lists 3 Toxicity, Drug clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT05512169

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.

Gender: All

Ages: 1 Year - 18 Years

Updated: 2026-01-15

ALL, Childhood
Pediatric Cancer
Toxicity, Drug
+5
RECRUITING

NCT05652673

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Gender: All

Ages: 18 Years - Any

Updated: 2025-02-28

Melanoma Stage IV
Melanoma Stage III
Immunotherapy
+1
RECRUITING

NCT04499885

Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning

Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning.

Gender: All

Updated: 2020-08-05

Toxicity, Drug